Genentech's Actemra gains US OK for expanded arthritis use
This article was originally published in Scrip
Executive Summary
Genentech, part of Roche, won US FDA approval to extend the labelling of its intravenous rheumatoid arthritis drug Actemra (tocilizumab), sold in Europe as RoActemra, as a treatment in combination with methotrexate to inhibit and slow structural joint damage, improve physical function and achieve major clinical response in adults with moderate to severe active forms of the disease.